Table 1 Demographics and disease characteristics
|  | Pegfilgrastim 6 mg | Filgrastim 5 μg/kg/day |
|---|---|---|
No. of Patients | 42 | 41 |
Age | Â | Â |
   Median (range), years | 51 (18–74) | 54 (19–79) |
   < 55 years, n (%) | 22 (52%) | 21 (51%) |
   ≥ 55 years, n (%) | 20 (48%) | 20 (49%) |
Male, n (%) | 22 (52%) | 17 (41%) |
Baseline ANC, × 109/L |  |  |
   Mean (SD) | 2.2 (5.4) | 2.3 (4.0) |
   Median (range) | 0.4 (0.0–33.8) | 1.0 (0.0–17.4) |
Most common FAB Type, n (%) | Â | Â |
   M1 | 9 (21%) | 9 (22%) |
   M2 | 8 (19%) | 11 (27%) |
   M4 | 12 (29%) | 4 (10%) |
   M4eo | 3 (7%) | 3 (7%) |
   M5 | 4 (10%) | 6 (15%) |
Cytogenetics, n (%) | Â | Â |
   Intermediate | 34 (81%) | 38 (93%) |
   Favorable | 7 (17%) | 3 (7%) |
   Unfavorablea | 1 (2%) | 0 (0%) |
Bone marrow cellularity, n (%) | Â | Â |
   Hypoplastic | 4 (10%) | 5 (12%) |
   Normoplastic | 4 (10%) | 8 (20%) |
   Hyperplastic | 33 (79%) | 28 (68%) |
   Unknown | 1 (2%) | 0 (0%) |